News
HOMENews
News
LyseNTech signed a joint research agreement with LegoChem Biosciences
LyseNTech / 2020-12-02
Nov 30, 2020
LyseNTech signed a joint research agreement with LegoChem Biosciences on the 27th to develop a new antibiotic drug using endolysin.
With this contract, LyseNTech and LegoChem Biosciences will jointly develop endolysin antibiotics for Gram negative bacteria as the first-in-class new drug.